Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Ozanimod
Drug ID BADD_D02580
Description Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) [L11025] and was approved by the FDA on March 26, 2020.[L12573,L12582] In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects.[A176474] Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting.[A189336] In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Indications and Usage Ozanimod is indicated for adults in the treatment of relapsing forms of MS, which may include relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive MS.[L12582]
Marketing Status approved; investigational
ATC Code L04AA38
DrugBank ID DB12612
KEGG ID D10968
MeSH ID C000607776
PubChem ID 52938427
TTD Drug ID D07EDB
NDC Product Code Not Available
UNII Z80293URPV
Synonyms ozanimod | RPC1063
Chemical Information
Molecular Formula C23H24N4O3
CAS Registry Number 1306760-87-1
SMILES CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CCC(C4=CC=C3)NCCO)C#N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Glucose tolerance impaired14.06.02.001; 05.06.02.0010.000241%
Gout15.01.06.001; 14.09.01.0010.000820%Not Available
Haematochezia24.07.02.012; 07.12.02.0030.001688%Not Available
Hallucination, visual19.10.04.0070.000241%Not Available
Headache17.14.01.0010.060085%
Hemiparesis17.01.04.0010.000482%
Hernia08.01.04.0010.000241%Not Available
Hypersomnia19.02.05.001; 17.15.01.0010.001760%
Hypertension24.08.02.0010.014322%
Hypertensive crisis24.08.01.0010.000482%Not Available
Hypoaesthesia23.03.03.081; 17.02.06.0230.019699%Not Available
Immune system disorder10.02.01.0010.001061%Not Available
Impaired healing08.03.02.0010.000530%Not Available
Increased appetite14.03.01.003; 08.01.09.0270.000530%Not Available
Increased tendency to bruise24.07.06.012; 23.06.01.009; 01.01.03.0050.000241%Not Available
Influenza like illness08.01.03.0100.003400%
Insomnia19.02.01.002; 17.15.03.0020.008969%
Irritable bowel syndrome19.24.01.003; 07.02.04.0030.001760%Not Available
Joint swelling15.01.02.0040.006389%Not Available
Lethargy17.02.04.003; 08.01.01.008; 19.04.04.0040.002869%
Leukopenia01.02.02.0010.001447%Not Available
Lip swelling10.01.05.005; 23.04.01.007; 07.05.04.0050.000940%Not Available
Liver disorder09.01.08.0010.001881%Not Available
Lymphopenia01.02.02.0020.012032%Not Available
Macular oedema06.04.06.0050.000844%Not Available
Mass08.03.05.0030.000820%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.012731%
Micturition urgency20.02.02.0060.001350%
Migraine24.03.05.003; 17.14.02.0010.012562%Not Available
Movement disorder17.01.02.0100.001230%Not Available
The 3th Page    First    Pre   3 4 5 6 7    Next   Last    Total 7 Pages